CY1110886T1 - Συνθεσεις για την καταπολεμηση της αντοχης στα αντιβιοτικα με μεσολαβηση β-λακταμασης, χρησιμοποιωντας αναστολεις β-λακταμασης χρησιμους για ενεση - Google Patents

Συνθεσεις για την καταπολεμηση της αντοχης στα αντιβιοτικα με μεσολαβηση β-λακταμασης, χρησιμοποιωντας αναστολεις β-λακταμασης χρησιμους για ενεση

Info

Publication number
CY1110886T1
CY1110886T1 CY20101101012T CY101101012T CY1110886T1 CY 1110886 T1 CY1110886 T1 CY 1110886T1 CY 20101101012 T CY20101101012 T CY 20101101012T CY 101101012 T CY101101012 T CY 101101012T CY 1110886 T1 CY1110886 T1 CY 1110886T1
Authority
CY
Cyprus
Prior art keywords
compositions
normally
sodium
gives
sulbactam
Prior art date
Application number
CY20101101012T
Other languages
English (en)
Inventor
Manu Chaudhary
Original Assignee
Venus Remedies Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Venus Remedies Limited filed Critical Venus Remedies Limited
Publication of CY1110886T1 publication Critical patent/CY1110886T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Η εφεύρεση περιγράφει σύνθεση για καταπολέμηση της αντοχής στα αντιβιοτικά με μεσολάβηση β-λακταμάσης χρησιμοποιώντας αναστολέα β-λακταμάσης χρήσιμο για ένεση, κατάλληλη για φαρμακευτική εφαρμογή. Η εφεύρεση σχετίζεται με φαρμακευτική σύνθεση που περιέχει κεφτριαξόνη (συνήθως ως νατριούχο κεφρτιαξόνη) και σουλβακτάμη (συνήθως ως νατριούχο σουλβακτάμη). Τέτοιου είδους συνθέσεις αποκαλύπτεται ότι είναι χρήσιμες για ενδομυϊκή ή ενδοφλέβια χορήγηση ως αντιβιοτικά για νοσηλευόμενους ασθενείς που πάσχουν από σοβαρές λοιμώξεις. Συγκεκριμένα, αυτή η εφεύρεση σχετίζεται με φαρμακευτικές συνθέσεις που περιλαμβάνουν περαιτέρω χηλικό παράγοντα αμινοκαρβοξυλικού οξέος, για παράδειγμα, αιθυλενο διαμινο τετραοξικό οξύ (EDTA), ή φαρμακευτικά αποδεκτό άλας αυτού. Οι φαρμακευτικές συνθέσεις αυτής της εφεύρεσης έχει διαπιστωθεί ότι συνήθως ενισχύουν την αντοχή στο σχηματισμό σωματιδίων σε διαλύματα που πρόκειται να χορηγηθούν παρεντερικά. Η εφεύρεση παρέχει επίσης λεπτομέρειες μορφών δόσης που φυλάσσονται σε σφραγισμένα δοχεία για ανασύσταση πριν τη χρήση. Η εφεύρεση παρέχει επίσης διαδικασία παρασκευής των συνθέσεων αυτών. Η εφεύρεση παρέχει μέθοδο θεραπείας ασθενούς που πάσχει από νόσημα ή διαταραχή, όπου ενδείκνυται θεραπεία με νατριούχο κεφτριαξόνη και νατριούχο σουλβακτάμη.
CY20101101012T 2004-12-02 2010-11-10 Συνθεσεις για την καταπολεμηση της αντοχης στα αντιβιοτικα με μεσολαβηση β-λακταμασης, χρησιμοποιωντας αναστολεις β-λακταμασης χρησιμους για ενεση CY1110886T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2411DE2004 2004-12-02
EP05817957A EP1841432B1 (en) 2004-12-02 2005-11-28 Compositions for combating beta-lactamase-mediated antibiotic resistance using beta-lactamase inhibitors useful for injection

Publications (1)

Publication Number Publication Date
CY1110886T1 true CY1110886T1 (el) 2015-06-10

Family

ID=35789266

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101101012T CY1110886T1 (el) 2004-12-02 2010-11-10 Συνθεσεις για την καταπολεμηση της αντοχης στα αντιβιοτικα με μεσολαβηση β-λακταμασης, χρησιμοποιωντας αναστολεις β-λακταμασης χρησιμους για ενεση

Country Status (23)

Country Link
US (2) US8273732B2 (el)
EP (1) EP1841432B1 (el)
JP (1) JP5269415B2 (el)
KR (2) KR20070067189A (el)
CN (1) CN101060846A (el)
AT (1) ATE476981T1 (el)
AU (1) AU2005310888B2 (el)
BR (1) BRPI0517128A (el)
CY (1) CY1110886T1 (el)
DE (1) DE602005022939D1 (el)
DK (1) DK1841432T3 (el)
ES (1) ES2349301T3 (el)
HR (1) HRP20100591T1 (el)
MX (1) MX2007006540A (el)
NZ (1) NZ555075A (el)
PL (1) PL1841432T3 (el)
PT (1) PT1841432E (el)
RS (1) RS51506B (el)
RU (1) RU2397768C2 (el)
SI (1) SI1841432T1 (el)
UA (1) UA91204C2 (el)
WO (1) WO2006059344A1 (el)
ZA (1) ZA200704394B (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030010176A (ko) * 2001-07-25 2003-02-05 이병두 은행 열매 추출물과 호도 열매 추출물을 이용한 천식 치료제
CN101129382B (zh) * 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
CN101129381B (zh) * 2006-08-25 2012-02-01 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
WO2010013640A1 (ja) * 2008-07-28 2010-02-04 Yamaguchi Keizo 感染症治療効果増強剤
CN101537009B (zh) * 2009-04-30 2010-09-15 海口奇力制药股份有限公司 注射用头孢曲松钠他唑巴坦钠复方制剂的生产工艺
JP2012176899A (ja) * 2009-05-19 2012-09-13 Mitsubishi Tanabe Pharma Corp ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
JP5767745B2 (ja) * 2011-05-28 2015-08-19 ウォックハート リミテッド 抗菌剤とタゾバクタムとを含む組成物
EP2768503A1 (en) * 2011-07-26 2014-08-27 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
WO2013042140A2 (en) * 2011-09-23 2013-03-28 Manu Chaudhary Non antibiotic,non peptide compounds for antibiotic efficacy & safety enhancement
MX353874B (es) 2012-03-26 2018-02-01 Santen Pharmaceutical Co Ltd Gotas para los ojos que contienen diquafosol.
ES2691493T3 (es) 2012-06-07 2018-11-27 Childrens Hospital Los Angeles Métodos para tratar la neutropenia usando agonistas retinoides
JP6186001B2 (ja) * 2012-09-27 2017-08-23 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． タゾバクタムアルギニン抗菌性組成物
AU2015219038B2 (en) 2014-02-18 2018-10-18 Children's Hospital Los Angeles Compositions and methods for treating neutropenia
KR20160130824A (ko) * 2014-03-29 2016-11-14 욱크하르트 리미티드 세페파임 또는 술박탐을 포함하는 제약학적 조성물
KR102160013B1 (ko) * 2014-04-03 2020-09-25 백스터 인터내셔널 인코포레이티드 주사액용 주머니 및 주사용 제제
US10201518B2 (en) 2016-09-28 2019-02-12 The University Of Hong Kong Bismuth(III) compounds and methods thereof
WO2018081944A1 (en) * 2016-11-02 2018-05-11 Xiangbei Welman Pharmaceutical Co., Ltd Composition composed of ceftriaxone sodium and sulbactum sodium
CN106822147B (zh) * 2016-11-03 2021-07-20 湘北威尔曼制药股份有限公司 一种头孢曲松钠和舒巴坦钠组合物、包含该组合物的药物制剂及其应用
RU2665006C1 (ru) * 2017-02-28 2018-08-24 Общество с ограниченной ответственностью "Супербаг Солюшенс" Композиция антимикробных препаратов для лечения инфекционных заболеваний людей и животных и способ её применения
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630510B1 (en) * 1999-10-28 2003-10-07 Merck & Co., Inc. Substituted succinic acid metallo-β-lactamase inhibitors and their use in treating bacterial infections
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
DK1468697T3 (da) * 2003-04-14 2008-04-14 Wyeth Corp Sammensætninger indeholdende piperacillin og tazobactam, der er anvendelige til injektion

Also Published As

Publication number Publication date
AU2005310888B2 (en) 2011-01-06
MX2007006540A (es) 2008-01-31
JP5269415B2 (ja) 2013-08-21
ES2349301T3 (es) 2010-12-29
RS51506B (en) 2011-06-30
UA91204C2 (ru) 2010-07-12
CN101060846A (zh) 2007-10-24
ATE476981T1 (de) 2010-08-15
BRPI0517128A (pt) 2008-09-30
DK1841432T3 (da) 2010-12-06
PT1841432E (pt) 2010-10-25
ZA200704394B (en) 2008-09-25
DE602005022939D1 (de) 2010-09-23
JP2008521884A (ja) 2008-06-26
RU2397768C2 (ru) 2010-08-27
EP1841432B1 (en) 2010-08-11
US20100160277A1 (en) 2010-06-24
PL1841432T3 (pl) 2011-01-31
RU2007124325A (ru) 2009-01-10
EP1841432A1 (en) 2007-10-10
WO2006059344B1 (en) 2006-11-02
KR20070067189A (ko) 2007-06-27
WO2006059344A1 (en) 2006-06-08
US20130023512A1 (en) 2013-01-24
KR101244362B1 (ko) 2013-03-18
AU2005310888A1 (en) 2006-06-08
NZ555075A (en) 2011-02-25
US8273732B2 (en) 2012-09-25
HRP20100591T1 (hr) 2010-12-31
KR20090101514A (ko) 2009-09-28
SI1841432T1 (sl) 2011-02-28
US9012442B2 (en) 2015-04-21

Similar Documents

Publication Publication Date Title
CY1110886T1 (el) Συνθεσεις για την καταπολεμηση της αντοχης στα αντιβιοτικα με μεσολαβηση β-λακταμασης, χρησιμοποιωντας αναστολεις β-λακταμασης χρησιμους για ενεση
CO5700796A2 (es) Composiciones que contienen piperacilina y tazobactam utiles para inyecciones
PH12013502449A1 (en) Novel method for preventing or treating m tuberculosis infection
JP2018138578A5 (el)
PE20050438A1 (es) Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
WO2007112000A3 (en) Treatment of pain
CY1110407T1 (el) Συνθεση για χορηγηση σιδηρου για την θεραπεια του συνδρομου σπασμωδικου σκελους
TW200639159A (en) Treatment of pain
MX2009012093A (es) Nuevos peptidos inhibidores de la replicacion del virus de la hepatitis c.
NO20071711L (no) Sammensetninger inneholdende piperacillin, tazobactam og en aminokarboksylsyre i et natriumlaktat fortynningsmiddel
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
CA2633077A1 (en) Solid-state form of amg 706 and pharmaceutical compositions thereof
ATE376422T1 (de) Diclazurilhaltige antiprotozoenmittel
CN1709263A (zh) 抗菌素组合物
WO2022177968A8 (en) Therapeutic methods
EA200300368A1 (ru) Применение аргинина при получении лекарственного средства для профилактики и лечения побочных эффектов, связанных с внутривенным введением фармацевтических препаратов
JP6179939B2 (ja) 高濃度γグロブリン製剤の粘度低下方法
PL1677808T3 (pl) Łączony preparat do leczenia sepsy
TH1701007800A (th) ตัวยับยั้งเมทัลโล-บีตา-แลคทาเมส
JP2010275289A (ja) エルタペネム及びβ−ラクタマーゼ阻害剤を有効成分として含む結核治療用混合製剤
UA84579C2 (ru) Макроциклические карбоновые кислоты и ацилсульфонамиды как ингибиторы репликации вируса гепатита с
AR051745A1 (es) Composiciones que contienen piperacilina y tazobactam utiles para inyeccion
TH86014A (th) สารผสมที่ประกอบด้วยปิปเปอราซิลลินและทาโซแบคแทมที่มีประโยชน์สำหรับการฉีด